The scenario of systemic therapy for prostate cancer is rapidly evolving, with new drugs
and new treatment options. To update the background knowledge of shared uro-oncologic practice,
we reviewed current statements and landmarks in systemic therapy. A number of new agents are under
investigation in non-metastatic and metastatic disease. Similarly, new target imaging technologies
are under development to improve the detection rate of true non-metastatic and true metastatic
patient. Five new drugs have shown to be effective on progression-free and overall survival in metastatìc
prostate cancer. However, the optimal sequencing of these treatments requires further investigation.
The tolerability and side effects of the new drugs are also crucial issues to be discussed,
as well as their activity against the disease. The uro-oncologic team has to stay updated
about new medical therapies in order to be confident in debating with other professionals involved
in prostate cancer decision making. Different points of view and nuances should be shared during
multidisciplinary group discussions to achieve a balanced decision in disease management.
Keywords: Prostate cancer, androgen deprivation therapy, antiandrogens, prostate cancer unit, docetaxel, systemic therapy.
Rights & PermissionsPrintExport